EMEA-002776-PIP01-20-M01
Key facts
| Active substance |
Autologous tumour-infiltrating lymphocytes (LN-144/LN-145)
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0363/2021
|
| PIP number |
EMEA-002776-PIP01-20-M01
|
| Pharmaceutical form(s) |
Dispersion for infusion
|
| Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Iovance Biotherapeutics, Inc.
E-mail: iova_regulatory_affairs@iovance.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|